Condition: Neuromuscular Disease · Neuromuscular Diseases (NMD) · Neurodegenerative Disease · Sponsor: Intellia Therapeutics
This study will be conducted to evaluate the efficacy and safety of a single dose of nexiguran ziclumeran (NTLA-2001) compared to placebo in participants with ATTRv-PN.
This description comes directly from the study's public registry record.
Trial Manager at Intellia · 1-857-285-6200 · medicalinformation@intelliatx.com
Always discuss trial participation with your own doctor first.
| Hospital Británico de Buenos Aires | Buenos Aires, Argentina | Recruiting |
| Hospital Italiano de Buenos Aires (HIBA) | Buenos Aires, Argentina | Recruiting |
| Hospital El Cruce | San Juan Bautista, Argentina | Recruiting |
| Hospital das Clinicas da Universidade Estadual de Campinas (UNICAMP) | Campinas, Brazil | Recruiting |
| HCFMRP - Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto | Ribeirão Preto, Brazil | Recruiting |
| Instituto de Educacao, Pesquisa e Gestao em Saude | Rio de Janeiro, Brazil | Recruiting |
| PSEG Centro de Pesquisa Clinica S.A. | São Paulo, Brazil | Recruiting |
| National Institute of Medical Sciences and Nutrition - Salvador Zubiran (INCMNSZ) | Tlalpan, Mexico | Recruiting |
| National University Hospital | Singapore, Singapore | Recruiting |
| Singapore General Hospital | Singapore, Singapore | Recruiting |
| National Taiwan University Hospital | Taipei, Taiwan | Active Not Recruiting |
| Taipei Veterans General Hospital | Taipei, Taiwan | Active Not Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06672237